RESULTS	Although the study was not powered for clinical outcomes ( n = 43 ) , the combined end point ( death , nonfatal infarction or repeat revascularization ) was encountered in 20 % of the patients receiving cytochalasin B and in 38 % of the patients receiving placebo .\